ABSTRACT
In recent years, several safety alerts have questioned or restricted the use of some pharmacological alternatives to allogeneic blood transfusion in established indications. In contrast, there seems to be a promotion of other alternatives, based on blood products and/or antifibrinolytic drugs, which lack a solid scientific basis. The Multidisciplinary Autotransfusion Study Group and the Anemia Working Group España convened a multidisciplinary panel of 23 experts belonging to different healthcare areas in a forum for debate to: 1) analyze the different safety alerts referred to certain transfusion alternatives; 2) study the background leading to such alternatives, the evidence supporting them, and their consequences for everyday clinical practice, and 3) issue a weighted statement on the safety of each questioned transfusion alternative, according to its clinical use. The members of the forum maintained telematics contact for the exchange of information and the distribution of tasks, and a joint meeting was held where the conclusions on each of the items examined were presented and discussed. A first version of the document was drafted, and subjected to 4 rounds of review and updating until consensus was reached (unanimously in most cases). We present the final version of the document, approved by all panel members, and hope it will be useful for our colleagues.
Subject(s)
Anemia/therapy , Critical Illness/therapy , Hemorrhage/therapy , Anemia/drug therapy , Antifibrinolytic Agents/adverse effects , Antifibrinolytic Agents/therapeutic use , Aprotinin/adverse effects , Aprotinin/therapeutic use , Blood Coagulation Factors/adverse effects , Blood Coagulation Factors/therapeutic use , Blood Transfusion/standards , Clinical Trials as Topic , Crystalloid Solutions , Erythropoietin/adverse effects , Erythropoietin/therapeutic use , Hematinics/adverse effects , Hematinics/therapeutic use , Humans , Hydroxyethyl Starch Derivatives/adverse effects , Hydroxyethyl Starch Derivatives/therapeutic use , Iron/adverse effects , Iron/therapeutic use , Isotonic Solutions/adverse effects , Isotonic Solutions/therapeutic use , Meta-Analysis as Topic , Observational Studies as Topic , Plasma Substitutes/adverse effects , Plasma Substitutes/therapeutic use , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Tranexamic Acid/adverse effects , Tranexamic Acid/therapeutic use , Transfusion ReactionABSTRACT
BACKGROUND: We have examined the variation in the promoter region in the gene encoding UGT-1, associated with Gilbert's syndrome, in Spanish population. PATIENTS AND METHOD: Blood DNA was obtained from 100 blood donors. Polymerase chain reaction (PCR) was used to examine the A(TA)nTAA motif in the promoter region of the UGT-1 gene. RESULTS: The frequency of the abnormal 7/7 genotype in Spanish population was 9%. The heterozygous 6/7 genotype was identified in 51% of the subjects. CONCLUSIONS: The frequency of the abnormal allele, similar in different caucasian populations, raise the question whether it would be worthwhile and cost-effective to introduce molecular screening for Gilbert's syndrome in the study of mild, chronic unconjugated hyperbilirubinemia, in the absence of haemolysis or evidence of hepatic injury.